Personalized treatment approach for HER2-positive metastatic breast cancer.

Pandey, P; Chaudhary, R; Tripathi, D; Lavudi, K; Dua, K; Weinfeld, M; Lavasanifar, A; Rajinikanth, PS

Personalized treatment approach for HER2-positive metastatic breast cancer.

Pandey, P Chaudhary, R Tripathi, D Lavudi, K Dua, K

Weinfeld, M Lavasanifar, A Rajinikanth, PS

Permalink

Publisher:: Springer Science and Business Media LLC
Publication Type:: Journal Article
Citation:: Med Oncol, 2024, 41, (11), pp. 252
Issue Date:: 2024-09-25

Closed Access

	Filename	Description	Size
	Personalised_ HER2_breast cancer.pdf	Published version	1.74 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Pandey, P
dc.contributor.author	Chaudhary, R
dc.contributor.author	Tripathi, D
dc.contributor.author	Lavudi, K
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Weinfeld, M
dc.contributor.author	Lavasanifar, A
dc.contributor.author	Rajinikanth, PS
dc.date.accessioned	2024-09-27T05:09:36Z
dc.date.available	2024-09-13
dc.date.available	2024-09-27T05:09:36Z
dc.date.issued	2024-09-25
dc.identifier.citation	Med Oncol, 2024, 41, (11), pp. 252
dc.identifier.issn	1357-0560
dc.identifier.issn	1559-131X
dc.identifier.uri	http://hdl.handle.net/10453/181048
dc.description.abstract	Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.
dc.format	Electronic
dc.language	eng
dc.publisher	Springer Science and Business Media LLC
dc.relation.ispartof	Med Oncol
dc.relation.isbasedon	10.1007/s12032-024-02504-4
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.classification	3211 Oncology and carcinogenesis
dc.subject.mesh	Humans
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Receptor, ErbB-2
dc.subject.mesh	Precision Medicine
dc.subject.mesh	Neoplasm Metastasis
dc.subject.mesh	Antineoplastic Agents, Immunological
dc.subject.mesh	Molecular Targeted Therapy
dc.subject.mesh	Biomarkers, Tumor
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Humans
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Neoplasm Metastasis
dc.subject.mesh	Receptor, erbB-2
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Female
dc.subject.mesh	Molecular Targeted Therapy
dc.subject.mesh	Biomarkers, Tumor
dc.subject.mesh	Precision Medicine
dc.subject.mesh	Antineoplastic Agents, Immunological
dc.title	Personalized treatment approach for HER2-positive metastatic breast cancer.
dc.type	Journal Article
utslib.citation.volume	41
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)/Associate Member
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Research Consortium in Complementary and Integrative Medicine (ARCCIM)
utslib.copyright.status	closed_access	*
dc.date.updated	2024-09-27T05:09:34Z
pubs.issue	11
pubs.publication-status	Published online
pubs.volume	41
utslib.citation.issue	11

Abstract:

Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181048